Recent performance snapshot
Avanos Medical (AVNS) has drawn fresh attention after a strong past 3 months, with the stock up 72.35% over that period and 121.38% year to date, compared with a last close of US$24.75.
Over the past year, the stock has returned 93.36%. The 3-year total return stands at 3.34%, and the 5-year total return reflects a decline of 38.51%. That backdrop sets the stage for a closer look at how the company’s current fundamentals line up with this recent share price performance.
See our latest analysis for Avanos Medical.
For investors, the key takeaway is that Avanos Medical shares have shown strong short term momentum, with the recent share price strength standing in contrast to more modest long term total shareholder returns.
If this kind of sharp shift in sentiment has your attention, it may be a good time to extend your watchlist with a few more potential opportunities using our screener for 34 healthcare AI stocks
With Avanos Medical shares surging in recent months while the company reports a loss of US$74.4 million on US$715.9 million of revenue, should you view the stock as undervalued, or has the market already priced in future growth?
Preferred Price-to-Sales of 1.6x: Is it justified?
On a P/S of 1.6x, Avanos Medical trades at a lower multiple than both the broader US Medical Equipment industry and its closest peers, even after the recent share price rally.
The P/S ratio compares the company’s market value with its revenue, which can be useful when earnings are negative, as is the case here. For a medical technology business generating US$715.9 million of revenue and currently reporting a loss of US$74.4 million, investors are effectively paying 1.6x annual sales for that exposure.
In this context, the stock sits below the US Medical Equipment industry average P/S of 2.8x and the peer average of 2.4x, yet above the estimated fair P/S of 1.2x. So while the market is valuing Avanos Medical at a discount to sector benchmarks, it is still assigning a premium to where the fair ratio model suggests the multiple could settle if expectations cool.
Explore the SWS fair ratio for Avanos Medical
Result: Price-to-Sales of 1.6x (ABOUT RIGHT)
However, you still need to weigh the recent loss of US$74.4 million and the relatively low value score of 2, which could limit how sentiment develops from here.
Find out about the key risks to this Avanos Medical narrative.
Next Steps
If this mix of strong recent returns and weaker long term results leaves you unsure, take a moment to review the data yourself and decide how comfortable you are with the trade off between price, growth potential and risk. Then check the 2 important warning signs.
Looking for more investment ideas?
If Avanos Medical has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to uncover other stocks that could fit your approach.
- Target potential bargains by scanning 46 high quality undervalued stocks that combine quality fundamentals with lower market expectations.
- Prioritise resilience by checking 66 resilient stocks with low risk scores that score well on volatility and financial risk factors.
- Spot future standouts early by reviewing the screener containing 21 high quality undiscovered gems before they attract broader attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com